Oral pretreatment with β-lactoglobulin derived peptide and CpG co-encapsulated in PLGA nanoparticles prior to sensitizations attenuates cow's milk allergy development in mice.

In splenocytes co-encapsulated BLG-Pep+CpG/NP lowered the percentage of Th2 cell while increasing ratios Treg/Th2 and Th1/Th2 The co-encapsulated BLG-Pep+CpG/NP pretreatment resulted in an increasing trend in CD25+FoxP3+ Treg percentage as compared to the BLG-Pep/NP+CpG/NP pretreated mice ( p =0.0518, Figure 5A ).The co-encapsulated BLG-Pep+CpG/NP pretreatment reduced the percentage of T1/ST2+ Th2 cells ( Figure 5B ) compared to the whey-sensitized group, but no difference was found on the frequencies of CXCR3+ Th1 ( Figure 5C ) and CD196+ Th17 subsets (Data not shown for Th17) in all pretreatment groups.

also in 63,971 other papers

A similar overall pattern was found for whey-specific IgE, albeit this did not reach statistical significance ( Figure 2C ).

also in 111,027 other papers